GlaxoSmithKline is now in “full countdown mode” to the demerger of its Consumer Healthcare business, according to CEO Emma Walmsley.
Two months on from GSK’s rejection of a £50bn ($68bn) bid for the business from Unilever – and with other...
GSK In 'Countdown Mode' To Consumer Split As Full Year Sales Slip Back
Listen to this article
Two months on from GSK’s rejection of a £50bn bid for Consumer Healthcare from Unilever – and with other suitors seemingly yet to materialize – CEO Emma Walmsley is pressing ahead with the plan to spin off the business in mid-2022. GSK will be buoyed by a strong showing by Consumer Healthcare in Q4, even through full year sales were down slightly.
Explore how consumer health is evolving. On the go.
More from Europe
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
• By
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
More from Geography
• By
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.